Nuclear Magnetic Resonance (NMR) spectroscopy is specified by the European Pharmacopoeia as the primary identification method for the aminoglycoside antibiotic tobramycin. This study demonstrates the straightforward application of that procedure using the benchtop Fourier 80 NMR spectrometer.
Image Credit: Forance/Shutterstock.com
It also addresses limitations of the current method and explores strategies to improve its robustness and reliability, leveraging the capabilities of the Fourier 80. With its compact, cryogen-free design, the Fourier 80 is well-suited for integration into routine Quality Control (QC) laboratories.
As a modern analytical instrument, the Fourier 80 not only supports compendial compliance for tests like tobramycin identification but also provides the adaptability needed to align with evolving regulatory expectations for both qualitative and quantitative analysis.
Download the full whitepaper here.
About Bruker BioSpin Division
The Bruker BioSpin Division designs, manufactures, and distributes advanced scientific instruments based on magnetic resonance, preclinical imaging technologies, and biosensor technologies. These include our industry-leading NMR and EPR spectrometers, imaging systems utilizing MRI, PET, SPECT, CT, Optical and MPI modalities, as well as molecular interaction technologies like SPR, switchSENSE® and single-cell Interaction Cytometry (scIC). The Division also offers integrated software solutions and automation tools to support digital transformation across research and quality control environments.
Our customers in academic, government, industrial, and pharmaceutical sectors rely on these technologies to gain detailed insights into molecular structure, dynamics, and interactions. Our solutions play a key role in structural biology, drug discovery, disease research, metabolomics, and advanced materials analysis. Recent investments in lab automation, optical imaging, and contract research services further strengthen our ability to support evolving customer needs and enable scientific innovation.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.